Form 4: Pfizer CFO David Denton Acquires Stock Appreciation Rights

Pfizer's Chief Financial Officer, David Denton, acquired stock appreciation rights (SARs) that will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date.

Summary

• On March 4, 2025, David M. Denton, the Chief Financial Officer & EVP of Pfizer Inc., acquired 413,138 stock appreciation rights (SARs).
• These SARs are subject to certain vesting requirements.
• The SARs will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, which is March 4, 2030.
• The exercise price of the SARs is $25.75.
• The reporting person has designated Shanice A. Reid as their attorney-in-fact for filing purposes.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating an executive's acquisition of stock appreciation rights, which is a common component of executive compensation. It doesn't inherently signal positive or negative sentiment, but rather provides information about insider transactions.

Positives

• The acquisition of stock appreciation rights by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, contingent on vesting requirements.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions, which are closely monitored by investors.

Comparison to Industry Standards

• Executive compensation packages often include stock options, restricted stock units (RSUs), and stock appreciation rights (SARs) to align management's interests with those of shareholders.
• Companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize similar equity-based compensation strategies for their executives.
• The specific terms and conditions of these grants, such as vesting schedules and exercise prices, can vary widely based on company performance and industry benchmarks.

Stakeholder Impact

• The acquisition of stock appreciation rights by the CFO could potentially align his interests more closely with those of shareholders, as the value of the rights is tied to the company's stock performance.

Key Dates